Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Safety and Efficacy Study of Oral ELND005 as an Adjunctive Maintenance Treatment in Patients With Bipolar I Disorder

NCT01674010 is registered in ClinicalTrials.gov with OPKO Health, Inc. as lead sponsor.

NCT NCT01674010
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01674010 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Safety and Efficacy Study of Oral ELND005 as an Adjunctive Maintenance Treatment in Patients With Bipolar I Disorder
Lead sponsor
OPKO Health, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
August 31, 2012
Completion date
June 30, 2014
Enrollment
309 (actual)
Sites
82

Conditions

As the registry lists them; a condition with its own page is linked.

bipolar 1 disorder